Tango Therapeutics
TNGX
121 hedge funds and large institutions have $781M invested in Tango Therapeutics in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 36 reducing their positions, and 15 closing their positions.
41% more call options, than puts
Call options by funds: $24K | Put options by funds: $17K
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
11% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 36
2.41% more ownership
Funds ownership: 92.29% → 94.7% (+2.4%)
1% more funds holding
Funds holding: 120 → 121 (+1)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
8% less capital invested
Capital invested by funds: $846M → $781M (-$64.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$23M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.68M |
| 4 |
SCM
Superstring Capital Management
New York
|
+$4.61M |
| 5 |
BlackRock
New York
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$22.4M |
| 2 |
AG
Artal Group
Luxembourg
|
-$21.6M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.74M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.84M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$2.99M |
TNGX Hedge Fund Activity: Q3 2024 in Review
121 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q3 2024, worth a combined $781M — down 7.7% from $846M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TNGX positions and 15 closed out — a net gain of 2 holders — while 40 added to existing stakes and 36 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $23M. The largest seller was TRV GP IV, cutting an estimated $22.4M.
- 121 institutional investors held Tango Therapeutics (TNGX) as of Q3 2024, up from 120 in Q2 2024.
- Funds reported $781M of Tango Therapeutics stock for Q3 2024, down 7.7% quarter-over-quarter.
- 17 funds opened new Tango Therapeutics positions in Q3 2024 and 15 closed out, a net change of +2 holders.
- The largest Tango Therapeutics buyer in Q3 2024 was Balyasny Asset Management, an estimated $23M added.
- The largest Tango Therapeutics seller in Q3 2024 was TRV GP IV, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2024.